Do analysts prefer BTAI or TLSA?

BioXcel Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 680.14%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BioXcel Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, BTAI or TLSA?

Tiziana Life Sciences has lower revenue, but higher earnings than BioXcel Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioXcel Therapeutics $640K 68.03 -$69.90M -$5.75 N/A Tiziana Life Sciences N/A N/A -$18.43M N/A N/A

Is BTAI or TLSA more profitable?

Tiziana Life Sciences has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -11,078.53% N/A -201.53% Tiziana Life Sciences N/A N/A N/A

Is BTAI or NRXP more profitable?

NRx Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics -11,078.53% N/A -201.53% NRx Pharmaceuticals N/A N/A -202.92%

BioXcel Therapeutics (BTAI) Competitors

$1.41 +0.01 (+0.71%)

Closing price 06/30/2026 04:00 PM Eastern

Extended Trading

$1.40 -0.01 (-0.64%)

As of 06/30/2026 07:27 PM Eastern

Compare

BTAI vs. TLSA, ENLV, SPRB, NRXP, and VTVT

Should you buy BioXcel Therapeutics stock or one of its competitors? MarketBeat compares BioXcel Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioXcel Therapeutics include Tiziana Life Sciences (TLSA), Enlivex Therapeutics (ENLV), Spruce Biosciences (SPRB), NRx Pharmaceuticals (NRXP), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does BioXcel Therapeutics compare to Tiziana Life Sciences?

BioXcel Therapeutics (NASDAQ:BTAI) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Tiziana Life Sciences has lower revenue, but higher earnings than BioXcel Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	68.03	-$69.90M	-$5.75	N/A
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A

BioXcel Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 680.14%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe BioXcel Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioXcel Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Tiziana Life Sciences has a beta of 0.44, suggesting that its share price is 56% less volatile than the broader market.

Tiziana Life Sciences has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Tiziana Life Sciences	N/A	N/A	N/A

30.7% of BioXcel Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Tiziana Life Sciences had 2 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat Tiziana Life Sciences' score of 0.63 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BioXcel Therapeutics	Very Positive
Tiziana Life Sciences	Positive

Summary

BioXcel Therapeutics and Tiziana Life Sciences tied by winning 6 of the 12 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Enlivex Therapeutics?

BioXcel Therapeutics (NASDAQ:BTAI) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Enlivex Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. Enlivex Therapeutics' return on equity of 248.08% beat BioXcel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
Enlivex Therapeutics	N/A	248.08%	206.39%

Enlivex Therapeutics has lower revenue, but higher earnings than BioXcel Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	68.03	-$69.90M	-$5.75	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

In the previous week, Enlivex Therapeutics had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for Enlivex Therapeutics and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat Enlivex Therapeutics' score of 0.93 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BioXcel Therapeutics	Very Positive
Enlivex Therapeutics	Positive

BioXcel Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, meaning that its share price is 47% more volatile than the broader market.

BioXcel Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 680.14%. Enlivex Therapeutics has a consensus price target of $16.50, indicating a potential upside of 2,900.55%. Given Enlivex Therapeutics' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than BioXcel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.7% of BioXcel Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 3.7% of BioXcel Therapeutics shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Enlivex Therapeutics beats BioXcel Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BioXcel Therapeutics compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Spruce Biosciences has a beta of 3.11, suggesting that its share price is 211% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market.

In the previous week, Spruce Biosciences had 1 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 2 mentions for Spruce Biosciences and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat Spruce Biosciences' score of 0.94 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Spruce Biosciences	Positive
BioXcel Therapeutics	Very Positive

Spruce Biosciences currently has a consensus target price of $163.00, suggesting a potential upside of 201.85%. BioXcel Therapeutics has a consensus target price of $11.00, suggesting a potential upside of 680.14%. Given BioXcel Therapeutics' higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Spruce Biosciences has higher revenue and earnings than BioXcel Therapeutics. Spruce Biosciences is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	30.24	-$38.97M	-$36.60	N/A
BioXcel Therapeutics	$640K	68.03	-$69.90M	-$5.75	N/A

Spruce Biosciences has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Spruce Biosciences beats BioXcel Therapeutics on 10 of the 16 factors compared between the two stocks.

How does BioXcel Therapeutics compare to NRx Pharmaceuticals?

BioXcel Therapeutics (NASDAQ:BTAI) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

BioXcel Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market.

30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 3.7% of BioXcel Therapeutics shares are held by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NRx Pharmaceuticals has higher revenue and earnings than BioXcel Therapeutics. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioXcel Therapeutics	$640K	68.03	-$69.90M	-$5.75	N/A
NRx Pharmaceuticals	$1.23M	120.47	-$28.62M	-$1.09	N/A

BioXcel Therapeutics currently has a consensus price target of $11.00, indicating a potential upside of 680.14%. NRx Pharmaceuticals has a consensus price target of $38.25, indicating a potential upside of 835.21%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than BioXcel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

NRx Pharmaceuticals has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%.

Company	Net Margins	Return on Equity	Return on Assets
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%
NRx Pharmaceuticals	N/A	N/A	-202.92%

In the previous week, NRx Pharmaceuticals had 4 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 5 mentions for NRx Pharmaceuticals and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat NRx Pharmaceuticals' score of 0.31 indicating that BioXcel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
BioXcel Therapeutics	Very Positive
NRx Pharmaceuticals	Neutral

Summary

NRx Pharmaceuticals beats BioXcel Therapeutics on 11 of the 15 factors compared between the two stocks.

How does BioXcel Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

vTv Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

vTv Therapeutics has higher revenue and earnings than BioXcel Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	145.43	-$26.97M	-$0.93	N/A
BioXcel Therapeutics	$640K	68.03	-$69.90M	-$5.75	N/A

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, vTv Therapeutics had 3 more articles in the media than BioXcel Therapeutics. MarketBeat recorded 4 mentions for vTv Therapeutics and 1 mentions for BioXcel Therapeutics. BioXcel Therapeutics' average media sentiment score of 1.87 beat vTv Therapeutics' score of 0.87 indicating that BioXcel Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
vTv Therapeutics	Positive
BioXcel Therapeutics	Very Positive

vTv Therapeutics has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. vTv Therapeutics' return on equity of 3.96% beat BioXcel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	3.96%	2.86%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

vTv Therapeutics presently has a consensus target price of $55.33, indicating a potential upside of 46.97%. BioXcel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 680.14%. Given BioXcel Therapeutics' higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

vTv Therapeutics beats BioXcel Therapeutics on 11 of the 16 factors compared between the two stocks.

Get BioXcel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BTAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BTAI vs. The Competition

Export

Metric	BioXcel Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$43.23M	$3.66B	$7.07B	$12.45B
Dividend Yield	N/A	2.20%	2.66%	6.16%
P/E Ratio	-0.25	20.90	27.25	24.87
Price / Sales	68.03	341.80	540.68	102.84
Price / Cash	N/A	143.77	48.53	58.59
Price / Book	-0.32	8.75	11.01	6.54
Net Income	-$69.90M	$23.81M	$3.57B	$336.70M
7 Day Performance	7.63%	3.60%	2.31%	2.88%
1 Month Performance	18.49%	3.72%	1.39%	0.64%
1 Year Performance	-28.43%	68.80%	36.71%	31.34%

BioXcel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BTAI BioXcel Therapeutics	2.5799 of 5 stars	$1.41 +0.7%	$11.00 +680.1%	-22.1%	$43.23M	$640K	N/A	90	Positive News
TLSA Tiziana Life Sciences	0.499 of 5 stars	$1.16 flat	N/A	-19.0%	$147.62M	N/A	N/A	8	Gap Down
ENLV Enlivex Therapeutics	3.3602 of 5 stars	$0.62 flat	$16.50 +2,554.0%	-50.9%	$147.58M	N/A	N/A	70
SPRB Spruce Biosciences	2.8521 of 5 stars	$52.36 flat	$163.00 +211.3%	+893.1%	$143.99M	$4.91M	N/A	20	High Trading Volume
NRXP NRx Pharmaceuticals	2.5954 of 5 stars	$3.97 flat	$38.25 +863.5%	+25.5%	$143.83M	$1.23M	N/A	2	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BTAI) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. TLSA, ENLV, SPRB, NRXP, and VTVT

How does BioXcel Therapeutics compare to Tiziana Life Sciences?

Summary

How does BioXcel Therapeutics compare to Enlivex Therapeutics?

Summary

How does BioXcel Therapeutics compare to Spruce Biosciences?

Summary

How does BioXcel Therapeutics compare to NRx Pharmaceuticals?

Summary

How does BioXcel Therapeutics compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioXcel Therapeutics (BTAI) Competitors

BTAI vs. TLSA, ENLV, SPRB, NRXP, and VTVT

How does BioXcel Therapeutics compare to Tiziana Life Sciences?

Which has better valuation & earnings, BTAI or TLSA?

Do analysts prefer BTAI or TLSA?

Which has more risk and volatility, BTAI or TLSA?

Is BTAI or TLSA more profitable?

Do institutionals and insiders believe in BTAI or TLSA?

Does the media favor BTAI or TLSA?

Summary

How does BioXcel Therapeutics compare to Enlivex Therapeutics?

Is BTAI or ENLV more profitable?

Which has higher valuation & earnings, BTAI or ENLV?

Does the media favor BTAI or ENLV?

Which has more volatility and risk, BTAI or ENLV?

Do analysts recommend BTAI or ENLV?

Do insiders & institutionals believe in BTAI or ENLV?

Summary

How does BioXcel Therapeutics compare to Spruce Biosciences?

Which has more volatility & risk, SPRB or BTAI?

Does the media prefer SPRB or BTAI?

Do analysts recommend SPRB or BTAI?

Which has higher valuation & earnings, SPRB or BTAI?

Is SPRB or BTAI more profitable?

Do insiders and institutionals hold more shares of SPRB or BTAI?

Summary

How does BioXcel Therapeutics compare to NRx Pharmaceuticals?

Which has more volatility & risk, BTAI or NRXP?

Do institutionals & insiders believe in BTAI or NRXP?

Which has better earnings and valuation, BTAI or NRXP?

Do analysts prefer BTAI or NRXP?

Is BTAI or NRXP more profitable?

Does the media favor BTAI or NRXP?

Summary

How does BioXcel Therapeutics compare to vTv Therapeutics?

Which has more volatility & risk, VTVT or BTAI?

Which has stronger valuation & earnings, VTVT or BTAI?

Do insiders & institutionals have more ownership in VTVT or BTAI?

Does the media refer more to VTVT or BTAI?

Is VTVT or BTAI more profitable?

Do analysts prefer VTVT or BTAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI vs. The Competition

BioXcel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools